Clinical Trials/NCT04572841

NCT04572841CompletedPhase 2

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjögren's Syndrome (pSjS)

Sanofi36 sites in 12 countries84 target enrollmentStarted: November 12, 2020Last updated: October 9, 2025

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 2
Status: Completed
Sponsor: Sanofi
Enrollment: 84
Locations: 36
Primary Endpoint: Change From Baseline to Week 12 in ESSDAI Score

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

Primary Objective:

To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI)

Secondary Objectives:

To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
To evaluate the therapeutic efficacy on fatigue of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
To evaluate the pharmacokinetic (PK) exposure of one dose level of SAR441344 over 12 weeks in adult patients with pSjS
To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo in adult patients with pSjS as determined by adverse events (AEs)
To evaluate the local tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS determined by electrocardiogram, vital signs, and laboratory evaluations
To measure the immunogenicity of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS

This is a multicenter, randomized, double blind, placebo controlled, parallel group proof of concept Phase 2 study to evaluate the therapeutic efficacy of SAR441344 in adult patients with primary Sjögren's syndrome (pSjS), as well as safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).

Study visit frequency: every 2 weeks in the treatment period and every 4 weeks in the follow-up period.
The total duration of the study will be 24 weeks (28 weeks including maximum screening duration) for each participant, including a 12-week treatment period and a 12-week follow-up period.

Study Design

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel
Primary Purpose: Treatment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages: 18 Years to 80 Years (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent.
•Diagnosis of pSjS according to the American College of Rheumatology/EULAR 2016 criteria at Screening.
•Disease duration since first diagnosis of pSjS ≤15 years based on medical history.
•Participants with moderate to severe disease activity set with ESSDAI total score ≥5, based on the following domains at Screening: glandular, articular, muscular, hematological, biological, and constitutional, lymphadenopathy.
•Seropositive for anti-Ro/SSA antibodies.
•IgG > lower limit of normal (ULN) at Screening.
•Stimulated salivary flow rate of ≥0.1 mL/min at Screening or Baseline.
•Body weight within 45 to 120 kg (inclusive) and body mass index within the range of 18.0 to 35.0 kg/m2 (inclusive) at Screening.
•Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•Capable of giving signed informed consent.

Exclusion Criteria

•Any autoimmune disease (except pSjS and Hashimoto thyroiditis) with or without secondary SjS.
•History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphospholipid syndrome and any participants requiring antithrombotic treatment.
•Active life threatening or organ threatening complications of pSjS disease at the time of Screening based on treating physician evaluation including but not restricted to:
•Vasculitis with renal, digestive, cardiac, pulmonary, or CNS involvement characterized as severe,
•Active central nervous system (CNS) or peripheral nervous system (PNS) involvement requiring high dose steroids,
•Severe renal involvement defined by objective measures,
•Lymphoma.
•Cardiac heart failure Stage III or IV according to the New York Heart Association.
•Severe pulmonary impairment documented by an abnormal pulmonary function test.
•Serious systemic viral, bacterial or fungal infection (eg, pneumonia, pyelonephritis), infection requiring hospitalization or IV antibiotics or significant chronic viral (including history of recurrent or active herpes zoster), bacterial, or fungal infection (eg, osteomyelitis) 30 days before and during Screening.
•Participants with a history of invasive opportunistic infections, such as, but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, and aspergillosis, regardless of resolution.
•Evidence of active or latent tuberculosis (TB) as documented by medical history (eg, chest X rays) and examination, and TB testing: A positive or 2 indeterminate QuantiFERON® TB Gold tests at Screening (regardless of prior treatment status).
•Evidence of any clinically significant, severe or unstable, acute or chronically progressive, uncontrolled infection or medical condition (eg, cerebral, cardiac, pulmonary, renal, hepatic, gastrointestinal, neurologic, or any known immune deficiency) or previous, active or pending surgical disorder, or any condition that may affect participant safety in the judgment of the Investigator (including vaccinations which are not updated based on local regulation).
•History or presence of diseases which exclude diagnosis of SjS as per the American College of Rheumatology/EULAR 2016 criteria including, but not limited to, sarcoidosis, amyloidosis, graft-versus-host disease, IgG4 related disease, and history of head and neck radiation treatment.
•History of systemic hypersensitivity reaction or significant allergies, other than localized injection site reaction, to any humanized monoclonal antibody.
•Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
•Any prior history of malignancy or active malignancy, including lymphoproliferative diseases and lymphoma (except successfully treated carcinoma in situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin) within 5 years prior to Baseline.
•Unstable dose of nonsteroidal anti inflammatory drugs (NSAIDs) and/or unstable use of topical and/or pharmacological stimulant treatment for salivary and lacrimal glands 4 weeks before Screening.
•High dose steroids, or a change in steroid dose within 4 weeks prior to Day 1/Randomization or expected changes during the course of the study.
•High dose of hydroxychloroquine or chloroquine, or methotrexate or change in hydroxychloroquine, chloroquine or methotrexate dose within 12 weeks prior to Day 1/Randomization or expected changes during the course of the study.
•Participants treated with the following medications/procedures prior to Screening:
•Previous treatment with azathioprine and other thiopurines, mycophenolate mofetil, sulfasalazine, or cyclosporine A within 3 months.
•Previous treatment with cyclophosphamide, leflunomide, or belimumab within 6 months.
•Previous treatment with rituximab within 12 months.
•Previous bone marrow transplantation, total lymphoid irradiation or ablative ultra high dose cyclophosphamide or IV Ig.
•Previous treatment with any other biologic drug within 5 times the half life of the drug.
•Received administration of any live (attenuated) vaccine within 3 months prior to Day 1/Randomization (eg, varicella zoster vaccine, oral polio, rabies).
•Clinically significant abnormal ECG or vital signs at Screening.
•Abnormal laboratory test(s) at Screening.
•Positive human immunodeficiency virus (HIV) serology (anti HIV1 and anti HIV2 antibodies) or a known history of HIV infection, active or in remission.
•Positive result on any of the following tests: hepatitis B surface antigen (HBsAg), anti hepatitis B core antibodies (anti HBc Ab), anti hepatitis C virus antibodies (HCV-Ab).
•If female, pregnant and/or breastfeeding.
•The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Arms & Interventions

SAR441344

Experimental

SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)

Intervention: SAR441344 (Drug)

Placebo

Placebo Comparator

Matching placebo

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Change From Baseline to Week 12 in ESSDAI Score

Time Frame: Baseline (Day 1) to Week 12

ESSDAI is validated and established outcome measurement for therapeutic efficacy in Sjögren's syndrome, evaluating disease activity mainly on extra-glandular manifestations. This score consists of 12 organ-specific domains (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral and central nervous system, hematological, biological), which are scored based on organ-specific items in 3 to 4 different severity grades (no, low, moderate, high; with 0=no and 3=high). These scores are summed up over all 12 domains in weighted way (severity grades are multiplied with weights ranging 1-6 depending on domain) to summarize into total score(0-123). Higher scores indicates worse outcome. Negative change from baseline indicates improvement. Baseline=Day 1 assessment value. Least squares (LS) mean is calculated using mixed models for repeated measures (MMRM). Observed values after occurrence of intercurrent events are excluded.

Secondary Outcomes

Change From Baseline to Week 12 in European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) Score(Baseline (Day 1) to Week 12)
Change From Baseline to Week 12 in Multidimensional Fatigue Inventory (MFI) General Fatigue Subscale and Other Subscales Score(Baseline (Day 1) to Week 12)
Mean Plasma Concentration of SAR441344(At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12)
Median Plasma Concentration of SAR441344(At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12)
Maximum Plasma Concentration (Cmax) of SAR441344(After the last SC dose on Week 10 up to 336 hours post-dose)
Time to Maximum Plasma Concentration (Tmax) of SAR441344(After the last SC dose on Week 10 up to 336 hours post-dose)
Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344(After the last SC dose on Week 10 up to 336 hours post-dose)
Terminal Half-life (t1/2z) of SAR441344(Week 10 to Week 12)
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events of Special Interest (AESI)(From first dose of IMP (Day 1) up to end of follow-up period (Week 24))
Number of Participants With Treatment Discontinuation and Withdrawals Due to TEAEs(From first dose of IMP (Day 1) up to end of follow-up period (Week 24))
Number of Participants With Increase in Pain Intensity Compared to Pre-dose Pain Intensity at Injection Site by Verbal Descriptor Scale (VDS)(Pre-dose (within 24 hours prior IMP dosing), post-dose (up to 15 minutes after dosing) and 2 hours post-dose at Weeks 2, 4, 6, 8 and 10)
Number of Participants With AEs Related to Local Tolerability Findings(Baseline (Day 1) to Week 10)
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs(Baseline (Day 1) to Week 24)
Number of Participants With PCSA in Electrocardiogram(Baseline (Day 1) to Week 24)
Number of Participants With PCSA in Hematology Parameters(Baseline (Day 1) to Week 24)
Number of Participants With PCSA in Clinical Chemistry Parameters(Baseline (Day 1) to Week 24)
Number of Participants With PCSA in Urinalysis Parameters(Baseline (Day 1) to Week 24)
Number of Participants With Anti-drug Antibodies (ADA) to SAR441344(Baseline, Week 4, Week 8, Week 12, and Week 24)

Investigators

Sponsor

Sanofi

Sponsor Class

Industry

Responsible Party

Sponsor

Study Sites (36)

Loading locations...

Similar Trials

Active, not recruiting

Phase 2

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisMultiple Sclerosis

NCT04879628Sanofi129

Active, not recruiting

Phase 2

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSystemic Lupus Erythematosus

NCT05039840Sanofi109

Completed

Phase 1

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy AdultsParoxysmal Nocturnal Hemoglobinuria

NCT06326814Sanofi54

Withdrawn

Phase 2

Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisType 2 Diabetes Mellitus

NCT03437720Sanofi

Active, not recruiting

Phase 1

Efficacy and safety of SAR441344 in the treatment of Systemic Lupus ErythematosusSystemic lupus erythematosus

EUCTR2021-001567-25-ESSanofi-Aventis Recherche et Développement166